Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.
2.

Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline [Internet].

Waites KB, Bade DJ, Bébéar C, Brown SD, Davidson MK, Duffy LB, Kenny G, Matlow A, Shortridge D, Talkington D, Totten PA, Watts JL, Zheng X.

Wayne (PA): Clinical and Laboratory Standards Institute; 2011 Oct.

3.
4.

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).

Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK, Mendes RE.

J Chemother. 2019 Jul;31(4):188-194. doi: 10.1080/1120009X.2019.1609740. Epub 2019 May 13.

PMID:
31079589
5.

Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections.

Shortridge D, Flamm RK.

Clin Infect Dis. 2019 Apr 8;68(Supplement_3):S200-S205. doi: 10.1093/cid/ciz003.

6.

Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016.

Shortridge D, Gales AC, Streit JM, Huband MD, Tsakris A, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S63-S68. doi: 10.1093/ofid/ofy343. eCollection 2019 Mar.

7.

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program.

Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S47-S53. doi: 10.1093/ofid/ofy270. eCollection 2019 Mar. Erratum in: Open Forum Infect Dis. 2019 May 20;6(5):ofz202. Zervos, Marcos [corrected to Zervos, Marcus].

8.

Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves.

Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ, Shortridge D.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02549-18. doi: 10.1128/AAC.02549-18. Print 2019 May.

PMID:
30858207
9.

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.

Huband MD, Pfaller MA, Shortridge D, Flamm RK.

J Glob Antimicrob Resist. 2019 Feb 27;19:56-63. doi: 10.1016/j.jgar.2019.02.017. [Epub ahead of print]

PMID:
30825698
10.

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

Pfaller MA, Flamm RK, Duncan LR, Shortridge D, Smart JI, Hamed KA, Mendes RE, Sader HS.

Diagn Microbiol Infect Dis. 2019 Jul;94(3):304-313. doi: 10.1016/j.diagmicrobio.2019.01.015. Epub 2019 Jan 26.

PMID:
30808530
11.

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.

Shortridge D, Duncan LR, Pfaller MA, Flamm RK.

Int J Antimicrob Agents. 2019 May;53(5):637-643. doi: 10.1016/j.ijantimicag.2019.01.015. Epub 2019 Feb 1.

PMID:
30716448
12.

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.

Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D.

Diagn Microbiol Infect Dis. 2019 May;94(1):93-102. doi: 10.1016/j.diagmicrobio.2018.11.021. Epub 2018 Nov 30.

PMID:
30642717
13.

Activity of fosfomycin when tested against US contemporary bacterial isolates.

Flamm RK, Rhomberg PR, Watters AA, Sweeney K, Ellis-Grosse EJ, Shortridge D.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):143-146. doi: 10.1016/j.diagmicrobio.2018.08.010. Epub 2018 Aug 28.

PMID:
30236530
15.

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.

Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00339-18. doi: 10.1128/JCM.00339-18. Print 2018 Aug.

16.

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.

Schechter LM, Creely DP, Garner CD, Shortridge D, Nguyen H, Chen L, Hanson BM, Sodergren E, Weinstock GM, Dunne WM Jr, van Belkum A, Leopold SR.

MBio. 2018 Apr 24;9(2). pii: e00583-18. doi: 10.1128/mBio.00583-18.

17.

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program.

Pfaller MA, Huband MD, Shortridge D, Flamm RK.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02327-17. doi: 10.1128/AAC.02327-17. Print 2018 Apr.

18.

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.

Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02125-17. doi: 10.1128/AAC.02125-17. Print 2018 Mar.

19.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01856-17. doi: 10.1128/AAC.01856-17. Print 2018 Jan.

21.
22.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK.

Braz J Infect Dis. 2017 Nov - Dec;21(6):627-637. doi: 10.1016/j.bjid.2017.06.008. Epub 2017 Sep 21.

23.

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01045-17. doi: 10.1128/AAC.01045-17. Print 2017 Nov.

24.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M.

J Glob Antimicrob Resist. 2017 Sep;10:186-194. doi: 10.1016/j.jgar.2017.05.025. Epub 2017 Jul 19.

PMID:
28735046
25.

Correlation between phenotypic antibiotic susceptibility and the resistome in Pseudomonas aeruginosa.

Jaillard M, van Belkum A, Cady KC, Creely D, Shortridge D, Blanc B, Barbu EM, Dunne WM Jr, Zambardi G, Enright M, Mugnier N, Le Priol C, Schicklin S, Guigon G, Veyrieras JB.

Int J Antimicrob Agents. 2017 Aug;50(2):210-218. doi: 10.1016/j.ijantimicag.2017.02.026. Epub 2017 May 26.

PMID:
28554735
26.

Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.

Shortridge D, Castanheira M, Pfaller MA, Flamm RK.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00465-17. doi: 10.1128/AAC.00465-17. Print 2017 Jul.

27.

Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa.

van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B, Hannum G, Zambardi G, Miller K, Enright MC, Mugnier N, Brami D, Schicklin S, Felderman M, Schwartz AS, Richardson TH, Peterson TC, Hubby B, Cady KC.

MBio. 2015 Nov 24;6(6):e01796-15. doi: 10.1128/mBio.01796-15.

28.

Population analysis of Escherichia coli isolates with discordant resistance levels by piperacillin-tazobactam broth microdilution and agar dilution testing.

Shubert C, Slaughter J, Creely D, van Belkum A, Gayral JP, Dunne WM, Zambardi G, Shortridge D.

Antimicrob Agents Chemother. 2014;58(3):1779-81. doi: 10.1128/AAC.02181-13. Epub 2013 Dec 16.

29.

International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.

Creely D, Zambardi G, van Belkum A, Dunne WM Jr, Peyret M, Gayral JP, Shortridge D, Shubert C.

Eur J Clin Microbiol Infect Dis. 2013 Aug;32(8):997-1002. doi: 10.1007/s10096-013-1837-5. Epub 2013 Feb 9.

PMID:
23397255
30.

Rapid clinical bacteriology and its future impact.

van Belkum A, Durand G, Peyret M, Chatellier S, Zambardi G, Schrenzel J, Shortridge D, Engelhardt A, Dunne WM Jr.

Ann Lab Med. 2013 Jan;33(1):14-27. doi: 10.3343/alm.2013.33.1.14. Epub 2012 Dec 17. Review.

31.

Comparison of three reference methods for testing susceptibility of staphylococci to trimethoprim-sulfamethoxazole.

Griffith R, Creely D, Revell P, Dunne WM, Shortridge D.

J Clin Microbiol. 2009 Nov;47(11):3726-8. doi: 10.1128/JCM.00451-09. Epub 2009 Sep 9.

32.

Correlation of cefoxitin MICs with the presence of mecA in Staphylococcus spp.

Swenson JM, Brasso WB, Ferraro MJ, Hardy DJ, Knapp CC, Lonsway D, McAllister S, Reller LB, Sader HS, Shortridge D, Skov R, Weinstein MP, Zimmer BL, Patel JB.

J Clin Microbiol. 2009 Jun;47(6):1902-5. doi: 10.1128/JCM.02304-08. Epub 2009 Apr 8.

33.

Detection of inducible clindamycin resistance in staphylococci by broth microdilution using erythromycin-clindamycin combination wells.

Swenson JM, Brasso WB, Ferraro MJ, Hardy DJ, Knapp CC, McDougal LK, Reller LB, Sader HS, Shortridge D, Skov R, Weinstein MP, Zimmer BL, Patel JB.

J Clin Microbiol. 2007 Dec;45(12):3954-7. Epub 2007 Oct 17.

34.

Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in an Era of Drug-Resistant Streptococcus pneumoniae.

Bonvehi P, Weber K, Busman T, Shortridge D, Notario G.

Clin Drug Investig. 2003;23(8):491-501.

PMID:
17535061
35.

Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates.

Zheng X, Freeman AF, Villafranca J, Shortridge D, Beyer J, Kabat W, Dembkowski K, Shulman ST.

J Clin Microbiol. 2004 Sep;42(9):4323-6.

36.
37.

Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.

McDermott PF, Bodeis SM, Aarestrup FM, Brown S, Traczewski M, Fedorka-Cray P, Wallace M, Critchley IA, Thornsberry C, Graff S, Flamm R, Beyer J, Shortridge D, Piddock LJ, Ricci V, Johnson MM, Jones RN, Reller B, Mirrett S, Aldrobi J, Rennie R, Brosnikoff C, Turnbull L, Stein G, Schooley S, Hanson RA, Walker RD.

Microb Drug Resist. 2004 Summer;10(2):124-31.

PMID:
15256027
38.

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone GG, Shortridge D, Flamm RK, Tanaka SK, Graham DY.

J Antimicrob Chemother. 1997 Aug;40(2):283-6.

PMID:
9301997
39.

PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial.

Stone GG, Shortridge D, Flamm RK, Beyer J, Ghoneim AT, Tanaka SK.

J Antimicrob Chemother. 1997 Aug;40(2):251-6.

PMID:
9301991
40.

PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin.

Stone GG, Shortridge D, Flamm RK, Beyer J, Stamler D, Tanaka SK.

Epidemiol Infect. 1997 Apr;118(2):119-24.

41.

A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori.

Stone GG, Shortridge D, Versalovic J, Beyer J, Flamm RK, Graham DY, Ghoneim AT, Tanaka SK.

Antimicrob Agents Chemother. 1997 Mar;41(3):712-4.

42.

Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori.

Stone GG, Shortridge D, Flamm RK, Versalovic J, Beyer J, Idler K, Zulawinski L, Tanaka SK.

Helicobacter. 1996 Dec;1(4):227-8.

PMID:
9432314
43.

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF.

Antimicrob Agents Chemother. 1996 Feb;40(2):477-80.

44.

Operational restructuring: a patient-focused approach.

Watson PM, Shortridge DL Jr, Jones DT, Rees RT, Stephens JT.

Nurs Adm Q. 1991 Fall;16(1):45-52. No abstract available.

PMID:
1956573
45.

The Indiana Living Will Act.

Robinson RD Jr, Shortridge DR.

Indiana Med. 1986 Aug;79(8):694-5. No abstract available.

PMID:
3745903
46.

Eyedrops containing corticosteroids with antibiotics.

Shortridge D.

Med J Aust. 1980 Aug 9;2(3):163. No abstract available.

PMID:
7421691
47.

The action of aminobenzacridines on the Furth rat leukaemia.

Shortridge D, Turner R, Green HN.

Br J Cancer. 1969 Dec;23(4):825-32. No abstract available.

48.

A method for concentrating cancer cells in sputum.

Kuper SW, Shortridge D.

Lancet. 1967 Nov 11;2(7524):999-1000. No abstract available.

PMID:
4168534
49.

Cytological examination of the sputum.

Oppenheimer EA, Kuper SW, Rigatto M, Shortridge D.

Lancet. 1967 Nov 11;2(7524):1001-2. No abstract available.

PMID:
4168519
50.

Effect of cyclophosphamide, 6-mercaptopurine or methotrexate on the Furth rat leukaemia.

Green HN, Shortridge D.

Nature. 1967 Jul 1;215(5096):71-2. No abstract available.

PMID:
6053409

Supplemental Content

Loading ...
Support Center